Calprotectin rapid test Archives - Buhlmann Diagnostics Corp

Tag: Calprotectin rapid test

Connect with BUHLMANN at DDW 2018

Digestive Diseases Week (DDW) 2018 BUHLMANN Diagnostics Corp  Booth: #2347 June 02-05, 2018 | Walter E. Washington Convention Center | Washington, DC Learn More Come by our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP and serum infliximab trough levels  (Additional trough level
Continue Reading

Announcing Enhancement to Quantum Blue® fCAL (Calprotectin) High Range Assay

Quantum Blue® fCAL High Range Enhancements BUHLMANN is happy to introduce a revised and enhanced version of our Quantum Blue® fCAL high range test (LF-CHR25) to the market.  The changes result in several beneficial features that not only further simplify the procedure but also improve performance characteristics.   Enhancements and Benefits: Sample dilution NOW in extraction
Continue Reading

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846. Highlights from this Publication “… we showed that the smartphone reader used by patients
Continue Reading

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Continue Reading

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to
Continue Reading

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue®  fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010
Continue Reading

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.  Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis.  2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from
Continue Reading

Comparison of Two Immunoassays for Measurement of Faecal Calprotectin in Detection of Inflammatory Bowel Disease: (Pre)-analytical and Diagnostic Performance Characteristics

Quantum Blue®  fCAL Citation Oyaert, M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.  Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014 Mar;52(3):391-7. doi: 10.1515/cclm-2013-0699. Highlight from this Publication “The Thermo Fisher device is not reliable for
Continue Reading

Comparative Study of the Quantum Blue Rapid Test and an Established ELISA Method

Quantum Blue®  fCAL Citation Coorevits, L, Baert F , Vanpoucke H.  Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clinical chemistry and laboratory medicine: CCLM / FESCC. . 2013 Apr; 51(4):825-31. DOI:10.1515/cclm-2012-0386. “…we may conclude that the POCT can serve as reliable alternative to the time consuming ELISA…” Highlight from
Continue Reading

Validation of a Point-of-Care Desk Top Device to Quantitate Fecal Calprotectin and Distinguish Inflammatory Bowel Disease from Irritable Bowel Syndrome

Quantum Blue®  fCAL Citation Sydora, M. J., Sydora BC, Fedorak RN, 2012, Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome, J Crohns Colitis. 2012 Mar;6(2):207-14. doi: 10.1016/j.crohns.2011.08.008. Highlight from this Publication “Quantum Blue Reader® calprotectin levels were available within 30 min and correlated
Continue Reading